NEW ORLEANS — Results showed patients who undergo arthroscopic rotator cuff repair may experience a reduction in pain and narcotic use with a postoperative cold therapy regimen.
“[Cold therapy] is something that actively decreases narcotic consumption, so we can theoretically prescribe less postoperatively,” Sara L. Edwards, MD, professor of orthopedic surgery at the University of California San Francisco, told Healio about results presented at the American Academy of Orthopaedic Surgeons Annual Meeting. “The whole goal is to not have patients get addicted. Rotator cuff surgery is the most

NEW ORLEANS — In a global cohort of people from 15 countries, 7% had coronary plaque despite a coronary artery calcium score of 0, according to results of a study presented at the American College of Cardiology Scientific Session.
Race/ethnicity, country and age were independent predictors of “false negatives” of coronary plaque despite a CAC score of 0, Lohendran (Logen) Baskaran, MBBS, from National Heart Centre Singapore, said during a presentation of data from the GPS-CAD study, whose rationale and design were simultaneously published in JACC: Asia.
“We previously found that race/ethnicity

DENVER — Litifilimab was superior to placebo for reducing skin disease activity in cutaneous lupus erythematosus, according to phase 2 data presented at the American Academy of Dermatology Annual Meeting.
“The study showed significant efficacy of litifilimab relative to placebo as early as 4 weeks. The medicine was well tolerated, and the rapid and significant improvement makes this potential therapeutic approach very exciting,” Victoria Werth, MD, MS, professor of dermatology at the Perelman School of Medicine at the University of Pennsylvania, said during a late-breaking research

SYD-101 significantly slowed the progression of myopia in younger children and quick progressors over 36 months, according to a press release from Sydnexis.
“The STAR trial provides compelling evidence that low-dose atropine can meaningfully slow myopia progression, particularly in younger children who are progressing quickly,” lead presentation author Tina Rutar, MD, pediatric ophthalmologist and partner at Cataract and Laser Institute of Southern Oregon, told Healio. “These findings help clarify which patients are most likely to benefit and support a more targeted, proactive approach to

DENVER — Adults with moderate to severe hidradenitis suppurativa experienced substantial long-term symptom relief and quality of life improvements with the investigational nanobody inhibitor sonelokimab, according to a speaker.
Data from the phase 3 VELA-1 and VELA-2 clinical trials, presented at the American Academy of Dermatology Annual Meeting, showed reductions in total abscess and inflammatory nodule counts for participants receiving sonelokimab (MoonLake Immunotherapeutics) by week 16 and continued improvements through week 40, with more than half of participants achieving Hidradenitis

DENVER — Once-daily oral zasocitinib for moderate to severe plaque psoriasis demonstrated rapid and durable skin clearance and a consistent safety profile, according to data presented at the American Academy of Dermatology Annual Meeting.
Zasocitinib (Takeda) is an investigational, highly selective oral tyrosine kinase 2 (TYK-2) inhibitor that blocks interleukin-23 and other pathways driving psoriasis. April W. Armstrong, MD, MPH, professor and chief of dermatology at the University of California, told Healio zasocitinib expands dermatologists’ ability to individualize treatment, “particularly

COPENHAGEN, Denmark — The addition of pembrolizumab to neoadjuvant chemotherapy followed by single-agent adjuvant pembrolizumab improved long-term outcomes for patients with resectable lung cancer.
The regimen extended EFS among all patients regardless of whether they achieved pathologic complete response, 5-year follow-up data from the randomized phase 3 KEYNOTE-671 showed.
The benefit also persisted regardless of patients’ baseline characteristics.
Use of pembrolizumab (Keytruda, Merck) — an anti-PD-1 antibody — in the adjuvant setting has demonstrated effectiveness for patients with non-small

NEW ORLEANS — A culturally and medically tailored meal program reduced hospitalizations among Navajo Nation residents with heart failure, primarily by reducing all-cause and heart failure hospitalization, a speaker reported.
The intervention reduced food insecurity and financial strain and improved HF symptoms among residents of the rural Navajo Nation with HF, according to results of a pragmatic, open-label, randomized trial presented at the American College of Cardiology Scientific Session.
“The enduring impacts of settler colonialism have produced adverse structural drivers, particularly

In a phase 2 trial, OCU410, a modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration, reduced lesion growth and size while slowing ellipsoid zone loss, according to a press release from Ocugen.
“This outcome represents meaningful clinical and scientific validation of OCU410 but also further validation of our broader modifier gene therapy platform, giving us strong conviction as we advance into phase 3 and potential registrational pathway,” Shankar Musunuri, PhD, MBA, chairman, CEO and cofounder of Ocugen, told Healio.
In the ArMaDa clinical trial, 51

Most underage users on social media can see posts promoting celebrity-owned alcohol brands, many of which are not disclosed as being advertisements, according to a study.
This may have a strong impact on young users, according to another study that showed young people are more likely to report wanting to drink after watching content from influencers that featured alcohol.
The studies illustrate how accessible content depicting alcohol is to youth, as current platform policies are not strong enough to prevent them from viewing this type of content, according to the researchers.
Typically,